Facilitating orphan drug development

AGADA BioSciences is a clinical research organization (CRO) housed within the Innovacorp Enterprise Center on Summer St on the Dalhousie University campus.

AGADA provides pre-clinical and clinical research and services to an international clientele of pharmaceutical and biotechnology companies, as well as stake holder foundations.

AGADA was initiated through a spin-off of a highly successful pre-clinical efficacy core facility at Children’s National Medical Center in Washington DC, designed and managed by Kanneboyina Nagaraju DVM PhD and Eric Hoffman PhD.

Founded in 2013, AGADA employs a dozen highly educated and motivated staff to carry out drug trials in mouse models of human disease.  Positive results typically become an important aspect of a company’s orphan drug application to the FDA or EMA, and a proof of principle of drug mechanism of action and therapeutic benefit.

In the 3rd year of operation, AGADA generated revenues of $2.3M, and shows a double digit annual growth rate.

AGADA is expanding services to support pharmacodynamic biomarker discovery and integration into both pre-clinical and clinical programs.  AGADA works closely with Dalhousie University, helping facilitate their growing rare disease and orphan drug development programs.

Website:

http://www.agadabio.com

Contact Information

AGADA Biosciences Inc.
1344 Summer St., Suite 312
Halifax, Nova Scotia
B3H 0A8

Amanda Mullen, Senior Manager of Operations
Phone: (902) 442-4011
Email: AMullen@agadabio.com

Recent News